Stevens & Bolton LLP‘s ’highly trained and dedicated team' covers the full array of life sciences areas, with capabilities spanning transactional, regulatory, IP, and commercial cross-border matters. The Guildford-based team is led by Charlotte Tillett, recognised for her IP and transactional expertise. Gustaf Duhs is experienced in competition and regulatory matters. Beverley Flynn and Keith Syson handle M&A and commercial matters, while Catherine Penny is experienced in regulatory issues and international arbitration.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘The team at Stevens and Bolton is very supportive and is able to provide advice on a range of matters. Its highly trained and dedicated team is always extremely responsive and deals with matters with an extreme level of care and diligence.’
‘They are excellent IP and life sciences lawyers with strong expertise and a practical approach. What makes the team unique is their deep understanding of both legal and industry-specific issues, which helps clients navigate complex matters with confidence. We appreciate their clear advice, responsiveness, and ability to handle cross-border work. ’
‘Willingness to understand the client pain points in a sector undergoing a period of regulatory change - working in untested waters to provide clarity. Effective use of counsel to consider the options, but honest when the answer is not what the client wants. Leverage of expertise within the firm to put the right team in place.’
‘Sarah Murray is highly intelligent and articulate, adopting an outcome-based approach to give the client comfort on quality and costs. Lorna Sleave is a homegrown talent adopting the pragmatic S&B approach that delights clients.’
‘We have worked closely with both Gustaf Duhs in competition and regulatory law and Charlotte Tillett on life sciences and intellectual property matters at Stevens & Bolton and consistently found them to be exceptional lawyers whose combination of legal expertise, commercial insight, and client-focused approach sets them apart in the market.’
'The team is very pleasant to work with, the support is excellent, and you can really sense the depth of their expertise.'
Key clients
- Richard Dimbleby Cancer Fund
- Clínica Baviera S.A.
- Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd.
- Insud Pharma SLU
- Lonza Biologics plc
- mAbxience Research, SL
- Mediq Healthcare UK Ltd
- SecurMed UK
- Accord Healthcare
- Exeltis
- Glenmark Pharmaceuticals Europe Ltd
- British Generic Manufacturers Association
Work highlights
Acting for Clínica Baviera S.A. on the €22.75m acquisition by its subsidiary Castellana Intermediación Sanitaria, S.L. of Eye Hospitals Group Ltd and its subsidiaries, trading as Optimax.
Acting for Clinigen Ltd on the £6.2m acquisition, by its subsidiary Clinigen Healthcare Ltd, of Kinesys Consulting Limited and its subsidiary, Kinesys Consulting NL B.V.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
Charlotte Tillett
Other key lawyers
Gustaf Duhs; Beverley Flynn; Keith Syson; Catherine Penny; Sarah Murray; Lorna Sleave